C3 and systemic lupus erythematosus: Research has previously shown that measuring complement activation products in complement-related diseases like SLE could be advantageous in terms of sensitivity and specificity as compared to measuring low levels of C3 and C4, since the levels of these proteins are the net result of both consumption and synthesis (11, 57–59).